Abstract 167P
Background
The study aimed to evaluate baseline and dynamic changes of serum neutrophil-to-lymphocyte ratio (NLR) level as biomarkers of response to anti-PD-1/PD-L1 blockade combined with anti-VEGF or tyrosine kinase inhibitors (TKIs) in advanced hepatocellular carcinoma (aHCC) patients and the potential relationship between NLR and serum cytokines.
Methods
We collected NLR level at baseline and week 3 since initial treatment as well as baseline serum cytokines in patients with aHCC treated with immune-targeted combination therapy from October 2018 to November 2021. The cutoff of baseline NLR was defined by median level. We defined both baseline NLR ≤ 2.63 as well as NLR decrease at week 3 as group1 (n = 30), baseline NLR ≤ 2.63 while NLR increase at week 3 as group2 (n = 27), baseline NLR > 2.63 while NLR decrease at week 3 as group3 (n = 38), both baseline NLR>2.63 as well as NLR increase at week 3 as group4 (n = 14).
Results
A total of 132 patients with aHCC received the immune-targeted combination therapy were included. Baseline high NLR was significantly associated with worse progression-free survival (PFS) (5.4 vs. 14.1 months, p < 0.001) and overall survival (OS) (11.3 vs. 27.7 months, p < 0.001), even after multivariate analysis. NLR level decreased significantly at week 3 in patients with complete response or partial response (CR/PR) (baseline vs. week3: 2.30 vs. 1.96, p = 0.006), no significant difference was shown in patients with progression disease (PD) (n = 18) (baseline vs. week3: 3.80 vs. 2.90, p = 0.157). Patients in group4 showed the worst treatment response, with no patients achieved CR/PR. Cytokines analysis showed that patients with baseline high NLR had significantly higher level of baseline serum IL-8 than those with low NLR (5.66 vs. 2.05 pg/ml, p = 0.001). Patients with baseline high IL-8 showed worse PFS (5.5 vs. 11.4 months, p =0.047) and OS (13.5 vs. 26.4 months, p = 0.001).
Conclusions
NLR is an independent prognostic factor for aHCC, the combination of dynamic change and baseline NLR may assist in screening out patients who are difficult to benefit from immune-targeted therapy. High baseline NLR may correlate with high baseline serum IL-8.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The CAMS Innovation Fund for Medical Sciences; The Translational Research Project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences; Beijing Natural Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract